Cryptogenic Organizing Pneumonia

Vincent Cottin, M.D., Ph.D. Jean-François Cordier, M.D.

1 Hospices Civils de Lyon, Louis Pradel Hospital, National Reference Centre for Rare Pulmonary Diseases, Competence Centre for Pulmonary Hypertension, Department of Respiratory Medicine, University Claude Bernard Lyon I, University of Lyon, Lyon, France

Abstract

Organizing pneumonia (OP) is a pathological pattern defined by the characteristic presence of buds of granulation tissue within the lumen of distal pulmonary airspaces consisting of fibroblasts and myofibroblasts intermixed with loose connective matrix. This pattern is the hallmark of a clinical pathological entity, namely cryptogenic organizing pneumonia (COP) when no cause or etiologic context is found. The process of intraalveolar organization results from a sequence of alveolar injury, alveolar deposition of fibrin, and colonization of fibrin with proliferating fibroblasts. A tremendous challenge for research is represented by the analysis of features that differentiate the reversible process of OP from that of fibroblastic foci driving irreversible fibrosis in usual interstitial pneumonia because they may determine the different outcomes of COP and idiopathic pulmonary fibrosis (IPF), respectively. Three main imaging patterns of COP have been described: (1) multiple patchy alveolar opacities (typical pattern), (2) solitary focal nodule or mass (focal pattern), and (3) diffuse infiltrative opacities, although several other uncommon patterns have been reported, especially the reversed halo sign (atoll sign). Definitive diagnosis is based on (1) a suggestive clinical radiological presentation, (2) the demonstration of the characteristic pathological pattern at lung histopathology, and (3) exclusion of possible causes. Transbronchial biopsies or a transthoracic biopsy may also contribute to the pathological diagnosis. Rapid clinical and imaging improvement is obtained with corticosteroid therapy. Because of the risk of misdiagnosing alternative conditions that may mimic OP, only typical cases may be managed without histopathological confirmation, and patients should be followed with particular attention paid to any clue of alternate diagnosis, especially in case of incomplete response to treatment. Patients and clinicians must be aware of frequent relapses after stopping corticosteroid treatment.

Keywords
- organizing pneumonia
- cryptogenic organizing pneumonia
- interstitial pneumonia
- disease
- connective tissue

Organizing pneumonia (OP) is a pathological pattern defined by intraalveolar buds of granulation tissue consisting of fibroblasts and myofibroblasts intermixed with loose connective matrix, especially consisting of collagen (► Fig. 1). The pathological pattern of OP is the hallmark of a characteristic clinical pathological entity that may occur in the absence of etiology—cryptogenic OP (COP)—or as a result of a determined cause of inflammatory disorder such as connective tissue disease (secondary OP). Because buds of granulation tissue are present within the lumen of distal airspaces including the bronchioles, COP had been formerly referred to as bronchiolitis obliterans with organizing pneumonia (BOOP), a nomenclature now abandoned, because OP (and not bronchiolitis) is clearly the major lesion of COP. The term bronchiolitis obliterans was also a source of confusion with bronchiolitis with airflow obstruction occurring, for example, after lung or hematopoietic stem cell transplantation.

Issue Theme Orphan Lung Diseases; Guest Editor, Jay H. Ryu, M.D.


ISSN 1069-3424.
The first partial descriptions of OP can be traced back to the lectures from Charcot in 1877–78. Pathological observations published at the beginning of the 20th century were mostly conducted during the autopsy of patients who had died from pneumococcal pneumonia before the era of antibiotic therapy. The initial intraalveolar material was described as consisting of fibrin, further colonized by fibroblasts and replaced by "fibrilated connective tissue," a description close to the current definition. OP has then been considered as a characteristic pathological pattern resulting from organization of an inflammatory exudate in the lumen of alveoli of unresolved pneumonia, yet with only moderate clinical relevance. COP was eventually described in case reports, individualized as a clinicopathological entity without any evident cause in 1983 by Davison et al, then by several other series.

Although it is not strictly interstitial, COP is included in the American Thoracic Society/European Respiratory Society international consensus classification of the idiopathic interstitial pneumonias because of its idiopathic nature and similarities that may occasionally tend to confuse COP (especially infiltrative forms of COP with progression to fibrosis) with interstitial pneumonias.

Although the epidemiology of COP is poorly known, the annual incidence of OP has been estimated to be 1.97/100,000 in the Icelandic population, with 1.10/100,000 and 0.87/100,000 for COP and for secondary OP, respectively.

Pathogenesis

**Originality of Organizing Pneumonia as a Model**

OP is a unique model of an inflammatory lung disease with intraalveolar fibrosis that is completely reversible with therapy. Indeed, OP is characterized by intraalveolar accumulation of intermixed fibroblasts and connective matrix, especially collagen that is dramatically reversible with corticosteroids (CSs) contrary to other presentations of fibrosing lung disorders and especially that of idiopathic pulmonary fibrosis (IPF) with a pathological pattern of usual interstitial pneumonia (UIP). Although the buds of granulation tissue of OP and the fibroblastic foci of UIP share some morphological features, the outcome of the disease process clearly differs, a crucial difference that has been addressed in relatively few biopathological studies.

**Three Stages of Pathogenesis**

The pathogenesis of the pathological lesions of COP has been reported schematically to go through three stages:

1. The early stage (injury phase) is characterized by the flooding in the alveolar lumen of plasma proteins (permeability edema), with imbalance of the coagulation and fibrinolytic cascades in favor of the activation of the coagulation process, with further fibrin deposits, which are then populated by migrating inflammatory cells (lymphocytes, neutrophils, some eosinophils, and occasionally plasma cells and mast cells). Fibrin deposition may be prominent, as in the acute fibrinous variant of OP. The fibrillar material mostly consists of fibronectin, type III collagen, and proteoglycans, with a minority of type I collagen. Morphological and ultrastructural studies indicate the denudation of the epithelial basal laminae and extensive necrosis of alveolar epithelial type I cells, suggesting that alveolar epithelial injury forming gaps within the basal lamina may be the first event triggering this process. Capillary endothelial injury is often associated with epithelial lesions. Hyaline membranes are not found, in contrast to diffuse alveolar damage (DAD).

2. The second stage (proliferating phase) corresponds to the formation of fibroinflammatory buds. Fibrin is progressively fragmented by macrophages and inflammatory cells. The extension of these fibroinflammatory buds is complete within 1–2 weeks and is predominantly observed in the lower lobes. The extensibility of these fibroinflammatory buds is complete within 1–2 weeks and is predominantly observed in the lower lobes.

The first partial descriptions of OP can be traced back to the lectures from Charcot in 1877–78. Pathological observations published at the beginning of the 20th century were mostly conducted during the autopsy of patients who had died from pneumococcal pneumonia before the era of antibiotic therapy. The initial intraalveolar material was described as consisting of fibrin, further colonized by fibroblasts and replaced by "fibrilated connective tissue," a description close to the current definition. OP has then been considered as a characteristic pathological pattern resulting from organization of an inflammatory exudate in the lumen of alveoli of unresolved pneumonia, yet with only moderate clinical relevance. COP was eventually described in case reports, individualized as a clinicopathological entity without any evident cause in 1983 by Davison et al, then by several other series.

Although it is not strictly interstitial, COP is included in the American Thoracic Society/European Respiratory Society international consensus classification of the idiopathic interstitial pneumonias because of its idiopathic nature and similarities that may occasionally tend to confuse COP (especially infiltrative forms of COP with progression to fibrosis) with interstitial pneumonias.

Although the epidemiology of COP is poorly known, the annual incidence of OP has been estimated to be 1.97/100,000 in the Icelandic population, with 1.10/100,000 and 0.87/100,000 for COP and for secondary OP, respectively.

Pathogenesis

**Originality of Organizing Pneumonia as a Model**

OP is a unique model of an inflammatory lung disease with intraalveolar fibrosis that is completely reversible with therapy. Indeed, OP is characterized by intraalveolar accumulation of intermixed fibroblasts and connective matrix, especially collagen that is dramatically reversible with corticosteroids (CSs) contrary to other presentations of fibrosing lung disorders and especially that of idiopathic pulmonary fibrosis (IPF) with a pathological pattern of usual interstitial pneumonia (UIP). Although the buds of granulation tissue of OP and the fibroblastic foci of UIP share some morphological features, the outcome of the disease process clearly differs, a crucial difference that has been addressed in relatively few biopathological studies.

**Three Stages of Pathogenesis**

The pathogenesis of the pathological lesions of COP has been reported schematically to go through three stages:

1. The early stage (injury phase) is characterized by the flooding in the alveolar lumen of plasma proteins (permeability edema), with imbalance of the coagulation and fibrinolytic cascades in favor of the activation of the coagulation process, with further fibrin deposits, which are then populated by migrating inflammatory cells (lymphocytes, neutrophils, some eosinophils, and occasionally plasma cells and mast cells). Fibrin deposition may be prominent, as in the acute fibrinous variant of OP. The fibrillar material mostly consists of fibronectin, type III collagen, and proteoglycans, with a minority of type I collagen. Morphological and ultrastructural studies indicate the denudation of the epithelial basal laminae and extensive necrosis of alveolar epithelial type I cells, suggesting that alveolar epithelial injury forming gaps within the basal lamina may be the first event triggering this process. Capillary endothelial injury is often associated with epithelial lesions. Hyaline membranes are not found, in contrast to diffuse alveolar damage (DAD).

2. The second stage (proliferating phase) corresponds to the formation of fibroinflammatory buds. Fibrin is progressively fragmented by macrophages and inflammatory cells. The extension of these fibroinflammatory buds is complete within 1–2 weeks and is predominantly observed in the lower lobes. The extensibility of these fibroinflammatory buds is complete within 1–2 weeks and is predominantly observed in the lower lobes.

The first partial descriptions of OP can be traced back to the lectures from Charcot in 1877–78. Pathological observations published at the beginning of the 20th century were mostly conducted during the autopsy of patients who had died from pneumococcal pneumonia before the era of antibiotic therapy. The initial intraalveolar material was described as consisting of fibrin, further colonized by fibroblasts and replaced by "fibrilated connective tissue," a description close to the current definition. OP has then been considered as a characteristic pathological pattern resulting from organization of an inflammatory exudate in the lumen of alveoli of unresolved pneumonia, yet with only moderate clinical relevance. COP was eventually described in case reports, individualized as a clinicopathological entity without any evident cause in 1983 by Davison et al, then by several other series.

Although it is not strictly interstitial, COP is included in the American Thoracic Society/European Respiratory Society international consensus classification of the idiopathic interstitial pneumonias because of its idiopathic nature and similarities that may occasionally tend to confuse COP (especially infiltrative forms of COP with progression to fibrosis) with interstitial pneumonias.

Although the epidemiology of COP is poorly known, the annual incidence of OP has been estimated to be 1.97/100,000 in the Icelandic population, with 1.10/100,000 and 0.87/100,000 for COP and for secondary OP, respectively.

Pathogenesis

**Originality of Organizing Pneumonia as a Model**

OP is a unique model of an inflammatory lung disease with intraalveolar fibrosis that is completely reversible with therapy. Indeed, OP is characterized by intraalveolar accumulation of intermixed fibroblasts and connective matrix, especially collagen that is dramatically reversible with corticosteroids (CSs) contrary to other presentations of fibrosing lung disorders and especially that of idiopathic pulmonary fibrosis (IPF) with a pathological pattern of usual interstitial pneumonia (UIP). Although the buds of granulation tissue of OP and the fibroblastic foci of UIP share some morphological features, the outcome of the disease process clearly differs, a crucial difference that has been addressed in relatively few biopathological studies.

**Three Stages of Pathogenesis**

The pathogenesis of the pathological lesions of COP has been reported schematically to go through three stages:

1. The early stage (injury phase) is characterized by the flooding in the alveolar lumen of plasma proteins (permeability edema), with imbalance of the coagulation and fibrinolytic cascades in favor of the activation of the coagulation process, with further fibrin deposits, which are then populated by migrating inflammatory cells (lymphocytes, neutrophils, some eosinophils, and occasionally plasma cells and mast cells). Fibrin deposition may be prominent, as in the acute fibrinous variant of OP. The fibrillar material mostly consists of fibronectin, type III collagen, and proteoglycans, with a minority of type I collagen. Morphological and ultrastructural studies indicate the denudation of the epithelial basal laminae and extensive necrosis of alveolar epithelial type I cells, suggesting that alveolar epithelial injury forming gaps within the basal lamina may be the first event triggering this process. Capillary endothelial injury is often associated with epithelial lesions. Hyaline membranes are not found, in contrast to diffuse alveolar damage (DAD).

2. The second stage (proliferating phase) corresponds to the formation of fibroinflammatory buds. Fibrin is progressively fragmented by macrophages and inflammatory cells. The extension of these fibroinflammatory buds is complete within 1–2 weeks and is predominantly observed in the lower lobes. The extensibility of these fibroinflammatory buds is complete within 1–2 weeks and is predominantly observed in the lower lobes.

![Photomicrograph of a lung biopsy in a patient with cryptogenic organizing pneumonia. (A) Typical organizing pattern with buds of granulation tissue in the distal air spaces (40 ×). (B) Bud of granulation tissue in alveolar space and connected to the alveolar septum (100 ×). (C) Extension of the granulation tissue from one alveolus to the next one through the interalveolar pores described by Kohn, so-called butterfly pattern (100 ×). (Photographs courtesy of F. Thivolet-Béjui, M.D., Lyon, France.)](image-url)
cells. Activated fibroblasts migrate through gaps of the basal lamina into the fragmented fibrin and inflammatory cells, where they proliferate, differentiate into myofibroblasts, and form cell clusters within the distal airspaces. Inflammatory cells and fibrin are progressively replaced by aggregated fibroblasts/myofibroblasts intermixed with a loose connective matrix tissue rich in collagen (especially collagen I), fibronectin, procollagen type III and proteoglycans. Alveolar epithelial cells proliferate, restoring the continuity of the alveolar capillary membrane and the integrity of the alveolar unit.

3. The third stage (mature phase) is characterized by “mature” fibrotic buds clearly delineated inside the alveolar space. Inflammatory cells and fibrin deposits are no longer found in alveolar buds, which are mostly constituted by typical myofibroblasts (with cytoplasmic filaments oriented toward the cell axis),9 organized in concentric rings alternating with layers of collagen bundles. At this stage the connective network consists of thin collagen-I fibers together with thinner fibrils of collagen and procollagen type III, and fibronectin.

4. In a fourth stage (resolution phase), this process resolves without significant sequelae, similar to reversible wound healing in the skin. The relative preservation of the alveolar basal laminae is considered to be required for the reversibility of the lesions.

**Comparison of Organizing Pneumonia to Fibroblastic Foci in Usual Interstitial Pneumonia**

Because OP is a reversible process and fibroblastic foci are considered to drive the irreversible fibrosing process in UIP, studies have aimed at comparing both types of lesions with the objective of identifying some of the key determinants of CS reversibility.

Proliferation of fibroblasts is comparable in the fibromyxoid lesions of COP and in fibroblastic foci of UIP; however, the rate of proliferation as measured by KI-67 staining is much lower in both COP and UIP than in DAD.12 Conversely, the apoptotic activity is increased in intraalveolar buds of COP as compared with UIP.13 The soluble form of Fas is significantly increased in the bronchoalveolar lavage (BAL) fluid of patients with COP as compared with IPF.14 The expression of the members of the death receptors family tumor necrosis factor-α (TNF-α) receptor-1 and Fas by alveolar macrophages is higher in OP than in controls or patients with IPF.15 The serum marker of epithelial alveolar apoptosis M30 (measuring the caspase-cleaved cytokeratin-18 fragments) is higher in patients with COP than in UIP.16 Altogether, these observations suggest that a difference in the balance between proliferation and apoptosis might be involved in the distinct outcomes of these entities.

The process of alveolar reepithelialization seems to be disturbed or delayed in UIP, whereas it effectively contributes to alveolar integrity and resolution of pathological lesions in COP. The extent of reepithelialization of intraluminal connective tissue lesions is greater in COP than in UIP17 Whereas regenerating epithelial cells of both COP and UIP are capable of synthesizing the laminin-5 γ2 chain (needed for adhesive connections to the underlying basement membrane),17 the origin of regenerating cells is unknown in COP. Regenerating cells in UIP covering fibroblastic foci are organized in disordered layering and of variable morphology, and they express surfactant protein-A17 but not the tumor suppressor and inhibitor of angiogenesis ING4 (inhibitor of growth family member-4).18 In contrast, regenerating cells in COP, which are layered in an orderly fashion with a flat shape reminiscent of alveolar epithelial cells type 1, express ING418 but not surfactant protein-A.17

Prominent capillarization is found in the newly formed intraalveolar fibromyxoid lesions in COP, reminiscent of the reversible granulation tissue in skin wound healing.19 in sharp contrast with fibroblastic foci in UIP where the vessels when present are found at the periphery of the lesion interfacing the interstitium. This angiogenic process may be mediated by the local production of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and Flk-1, and basic fibroblast growth factor (bFGF), which are more strongly expressed in intraluminal fibromyxoid connective tissue of COP than in UIP.20

The pattern of matrix metalloproteinases (MMPs) expressed in OP is characterized by a predominance of MMP2 in BAL fluid and in tissues,21 in contrast with overproduction of MMP9 in UIP. However, elevated levels of MMP9 may also be found in the BAL fluid of patients with COP.22 Levels of the tissue inhibitor of MMPs (TIMP)-1 were also elevated in one study.22 Overall, OP may be considered as a model of normal wound repair contrasting with the uncontrolled aberrant repair and fibrosing process observed in UIP/IPF.23

**From Animal Models to Human Observations**

Models of postinfectious OP have been developed in animals inoculated with viruses, namely the intranasal inoculation of moderate doses of reovirus serotype 1 in a susceptible strain of mice (CBA/J),24,25 the inoculation of Streptococcus pneumoniae in Wistar rats,26,27 the slow resolution of pneumonia due to Legionella pneumophila in Toll-like receptor-5–deficient mice,28 and the persistent lung infection of pigs with circovirus.29 These experimental observations strongly suggest that the genetic background may participate in the pathogenesis of OP, at least in animals, demonstrate the role of T cells,30,31 and indicate that the intensity of the initial epithelial injury (especially alveolar epithelial cells type 2) and yet undetermined factors inherent to the host may influence the evolution to either OP or DAD.

Fewer data regarding biopathology are available in patients with OP. Studies have demonstrated the involvement of T cells,32 the secretion of platelet-derived growth factor (PDGF), TNF-α, and interleukin (IL)-8 by alveolar macrophages33,34; the presence in BAL fluid of monocyte chemotactic protein-1 (MCP-1), IL-10, IL-12, and IL-1835; and the release of tryptase by mast cells.36

**Areas of Uncertainties**

The cellular origin of fibroblasts that populate the distal airspaces in COP is unclear. The respective contributions of proliferating lung fibroblasts, fibrocytes or bone-marrow-
derived fibroblasts, and epithelial–mesenchymal transition have not been evaluated in OP. The mechanism by which CSs facilitate the rapid resolution of OP is also unclear, although apoptosis is likely, with the cells concerned remaining to be identified.

Whether the pathophysiology of COP and secondary OP are comparable is also unknown. Although COP and secondary OP appear very similar, the microvascular density and the density of collagen fibers within intraalveolar airspaces may be higher in secondary OP than in COP.

**Clinical Features**

Clinical features are generally consistent in various series of COP. The mean age of onset of COP is ~50 to 60 years, with rare cases reported in children. There is no sex predisposition. COP is generally more common in non-smokers or ex-smokers, especially in female patients. However, the frequency of the disease has not been adjusted for the prevalence of tobacco smoking in the different countries. More anecdotally, a seasonal relapse in early spring, and catamenial OP have been reported.

The initial manifestations are nonspecific, with the progressive onset of mild fever, cough, malaise, anorexia, weight loss, and progressive and usually mild dyspnea. Focal and sparse crackles are frequently found at auscultation over involved areas, with rarely clinical features of consolidation. Finger clubbing is absent. In most cases, the duration of onset is less than 3 months, with a subacute onset over a few weeks. The diagnosis is often delayed by 6 to 12 weeks, infectious pneumonia being the most common differential diagnosis, and in many cases the diagnosis is considered after the patients have received antibiotics. Dyspnea may occasionally be severe, especially in rapidly progressive forms of disease. Hemoptyis, chest pain, night sweats, and pneumothorax or pneumomediastinum are rare. When present and prominent, arthralgias or myalgias should raise the suspicion of connective tissue disease (CTD). OP can be the inaugural manifestation of CTD.

**Imaging Features**

Computed tomography (CT) of the chest is normal in less than 10% of cases. The imaging features of COP have been separated into three main characteristic patterns, namely multiple alveolar opacities (typical COP), solitary opacity (focal COP), and infiltrative opacities (infiltrative COP). In addition, COP may present with a variety of less common features on high-resolution CT (HRCT) shared with other diagnoses.

The most typical imaging pattern of COP consists of multiple patchy alveolar opacities (Fig. 2), with a density ranging from ground glass to consolidation with air bronchograms. These are usually bilateral, with a subpleural distribution (Fig. 3) and no predominant craniocaudal distribution. When migratory (i.e., with some opacities attenuating or clearing, while others appear in different areas), such multiple patchy alveolar opacities are so characteristic that they should immediately suggest the diagnosis of COP. Indeed, the correct diagnosis of COP could be made in 79% of cases in a series of idiopathic interstitial pneumonia. The size of the opacities varies from 1 to 2 cm to lobar opacities. An air bronchogram is often present in consolidations that correspond pathologically to intraalveolar buds of granulation tissue within the distal airspaces. Patchy areas of ground-glass opacities are frequently observed, corresponding pathologically to the infiltration of alveolar wall by inflammatory cells with some OP in the distal airspaces. Small nodular opacities may be seen.

The second typical (yet less frequent) imaging pattern of COP is a solitary focal nodule or masslike area of consolidation. The diagnosis is most frequently obtained by surgical resection of a solitary asymptomatic lesion mimicking lung carcinoma, especially when associated with hypermetabolism on positron emission tomography, especially alveolar cell adenocarcinoma. Focal COP is often located in the upper lobes and likely represents nonresolving infectious pneumonia in most cases; however, recollection by patients of a history of respiratory infection is uncommon. Air bronchogram may be present, but it does not rule out the possibility of cancer. Focal COP can be differentiated from round atelectasis at imaging. Focal COP may regress spontaneously or with CS therapy and usually does not relapse after surgical excision or medical therapy.

The third imaging presentation of COP (infiltrative or progressive fibrotic COP) is characterized on HRCT by a mixed pattern of interstitial opacities associated with superimposed alveolar opacities, which may consist of a network of bowed

**Table 1** High-Resolution Computed Tomographic Patterns in Organizing Pneumonia

<table>
<thead>
<tr>
<th>Typical pattern (most common)</th>
<th>Patchy alveolar opacities (typical COP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Less common patterns</td>
<td>Solitary opacity (focal COP)</td>
</tr>
<tr>
<td></td>
<td>Infiltrative opacities (infiltrative COP)</td>
</tr>
<tr>
<td>Rare patterns</td>
<td>Reversed halo sign or atoll sign</td>
</tr>
<tr>
<td></td>
<td>Progressive fibrosis with reticulation and areas of consolidation</td>
</tr>
<tr>
<td></td>
<td>Multiple nodules</td>
</tr>
<tr>
<td></td>
<td>Multiple masses or nodules</td>
</tr>
<tr>
<td></td>
<td>Bronchocentric consolidation</td>
</tr>
<tr>
<td></td>
<td>Irregular lines or bands</td>
</tr>
<tr>
<td></td>
<td>Perilobular opacities</td>
</tr>
</tbody>
</table>

COP, cryptogenic organizing pneumonia.
or polygonal opacities with poorly defined margins and bordering the interlobular septa (Fig. 4). Such pattern predominates in the lower lung zones. Honeycombing is not present. Although difficult to describe, this pattern may be recognized by the experienced clinician, especially in the context of OP associated with idiopathic inflammatory myopathy (with or without overt skin and/or muscle disease). The pathological correlate of these imaging features is often that of OP overlapping with idiopathic nonspecific interstitial pneumonia (NSIP), where the presence of associated OP in addition to interstitial cellular infiltration is common. This pattern is especially observed in the pulmonary manifestations of idiopathic inflammatory myopathy, which may precede the muscular manifestations. Therefore autoantibodies associated with idiopathic inflammatory myopathy (especially antisynthetase antibodies) should be searched in all patients with infiltrative OP.

In addition to the classical imaging presentations of COP, a variety of other imaging features have been reported. The reversed halo sign or atoll sign, consisting of a circular consolidation pattern (corresponding pathologically to OP in the distal airspaces) surrounding an area of ground-glass opacities (corresponding to alveolar wall inflammation), has been considered highly suggestive of the diagnosis (Fig. 5), especially in the absence of nodules that may be more frequently associated with tuberculosis. However, it can also be observed in a variety of other conditions, including tuberculosis, infectious pneumonia, paracoccidioidomycosis,
aspergillosis, alveolar cell adenocarcinoma, granulomatosis with polyangiitis (Wegener’s), and pulmonary sarcoidosis. Several less common imaging presentations of COP have been occasionally reported.1,62 None of these patterns is specific enough to suggest the diagnosis of COP on imaging.

Differential Diagnosis

The main differential diagnosis of COP presenting with migratory alveolar opacities (→Table 2) is with idiopathic chronic eosinophilic pneumonia (CEP), which is associated with asthma in 75% of cases; the correct diagnosis of CEP is provided by blood eosinophilia usually >1500 /mm³ and alveolar eosinophilia >25% and often >40%.78,79 However, some overlap is common between OP and CEP64,80–84 with possible elevation of eosinophil cells in the BAL (usually mild) in patients with COP, and conversely possible organization of the alveolar inflammatory exudate in CEP (less prominent than in COP). Both conditions also share a high frequency of relapse. Other conditions characterized by multiple alveolar opacities mostly include low-grade pulmonary lymphoma, and alveolar cell (pneumonic-type) adenocarcinoma, and rarely vasculitis, mycobacterial infection, or sarcoidosis.

Focal OP must be differentiated from primary lung cancer, metastatic lung tumor, lymphoma, and pulmonary infection. In patients with nonclassical imaging presentations of COP, a wide range of alternate diagnoses can be discussed.

Pulmonary Function Tests

Lung function tests in COP show a mild to moderate restrictive ventilatory pattern and may occasionally be normal.3–6,37,46,47,54,85–88 The carbon monoxide transfer factor is generally reduced. The carbon monoxide transfer coefficient is usually normal. Hypoxemia is usually mild. More severe hypoxemia may be present in patients with diffuse infiltrative opacities (infiltrative COP). Furthermore, in some patients with typical COP, severe hypoxemia (usually well tolerated) may result from defective vasoconstriction and right-to-left shunting in perfused and nonventilated areas of lung consolidation, as demonstrated by increased alveolar–arterial oxygen difference while breathing 100% oxygen contrasting with negative contrast echocardiography.89

Biological Features

Elevation of erythrocyte sedimentation rate, C-reactive protein serum level,83,90 and peripheral blood neutrophil count...
is common; however, these are nonspecific. There is no peripheral blood eosinophilia. Autoantibodies are usually negative.

The BAL differential cell count typically demonstrates a mixed pattern, consisting in increased percentage of lymphocytes (20 to 40%), neutrophils (~10%), and possibly eosinophils (~5%). The percentage of lymphocytes is usually higher than that of eosinophils in patients with COP but may be higher in cases overlapping with CEP. The presence of a small percentage of plasma cells or especially mast cells is remarkable. The CD4+/CD8+ ratio of lymphocytes is usually decreased in the BAL but it does not contribute significantly to the diagnosis.

Because the BAL cell count does not establish the diagnosis of OP, its main role is to exclude other diagnoses and to contribute to search for possible causes. BAL cultures may demonstrate active infection. Cytological and immunocytochemical analysis of BAL may show the presence of low-grade lymphoma or alveolar cell carcinoma. The BAL also differentiates COP from CEP.

**Diagnosis**

The diagnosis of COP is based on (1) a clinical radiological presentation suggestive of OP, (2) the demonstration of a pathological pattern of OP at histopathology of the lung, and (3) exclusion of possible causes of OP.

**Obtaining Lung Tissue**

Video-assisted thoracoscopic (VATS) is the method of choice to obtain lung tissue of sufficient size to evaluate the distribution of the lesions and the lung architecture. It is the most appropriate procedure to both definitely diagnose OP and exclude other processes. As in other idiopathic interstitial pneumonias, the lung biopsy should be performed in several lobes, be done before CSs are initiated, and be guided by preoperative CT of the chest, especially in cases of focal lesions. Although VATS is recommended for the definite histopathological diagnosis of OP, this invasive procedure is not always necessary, and a proportion of cases are managed empirically.

Transbronchial biopsies (TBBs) may be useful in patients with suspected COP and may obviate the need for VATS. Typical buds of granulation tissue may be observed on specimens of limited size and are characteristic enough to make a provisional diagnosis of OP in most cases. However, the sensitivity and specificity of TBBs for the diagnosis of OP have not been rigorously evaluated, and small specimens increase the risk of missing the central diagnosis. Because their small size does not allow exclusion of other histopathological processes coexisting with foci of OP, informative TBBs should be considered diagnostic of OP only in patients with a typical clinical and imaging profile. The diagnosis must be reconsidered in case of unexpected evolution, especially lack of complete resolution under CS therapy.

Core needle biopsy is generally safe and may be appropriate in a minority of patients with suspected OP, especially with focal consolidation at imaging. Lung specimens obtained by core needle biopsy are much larger than TBBs, and these may allow a more confident pathological diagnosis. However, published experience of this diagnostic method is limited. Microbiological analysis should also be performed on the lung specimen.

Overall, fiberoptic bronchoscopy (which excludes any bronchial obstruction) with BAL (including differential cell count and cultures) is recommended in any patient in whom COP is suspected. When bronchoscopy is performed, TBBs should be considered. The association of a typical clinical radiological pattern and a mixed lymphocytic pattern at BAL differential cell count, such as a marked increase in lymphocytes (~40%) and a mild increase in neutrophils (~4 to 10%) and eosinophils (~1 to 5%) is considered highly suggestive of OP (and of COP in the appropriate clinical context). VATS lung biopsy is considered if a pathological diagnosis of OP has not been obtained. The role of a core needle biopsy in this setting has not been established, and it may be used as a less invasive...
procedure in patients with comorbidities or those who decline thoracoscopy. When the lung biopsy is available, the diagnosis of COP should be eventually established through multidisciplinary discussion involving the clinician, radiologist, pathologist, and thoracic surgeon\(^7\) in atypical cases. However, in most cases the pathological diagnosis of OP is straightforward. Such a multidisciplinary approach is particularly useful in cases of COP with pathological features overlapping with CEP, NSIP, or DAD.

**Histopathological Diagnosis of Organizing Pneumonia**

When performed, histopathological analysis of the lung biopsy demonstrates buds of granulation tissue consisting of fibroblasts and myofibroblasts embedded in connective tissue,\(^7,102,103\) which are the hallmark of OP. One typical pathological feature of OP is the extension of the granulation tissue from one alveolus to the next one through the interalveolar pores described by Kohn,\(^1\) the so-called butterfly pattern.\(^10\) Although predominantly involving the alveoli, the granulation tissue often extends to adjacent bronchioli, the lumen of which is obstructed, hence the now abandoned terminology of BOOP. The overall architecture of the lung is preserved. Mild infiltration of the alveolar interstitium by inflammatory cells may be present. Foamy alveolar macrophages are often found in areas where alveoli are not filled with granulation tissue.

Outside the areas of the lung involved by OP, the histology of the lung is normal or characterized by mild inflammation. Additional findings suggestive of another diagnosis in secondary OP include necrosis or microabscesses (infectious process, necrotizing vasculitis) and organic debris (occult secondary OP include necrosis or microabscesses (infectious process, necrotizing vasculitis) and organic debris (occult sensitiveness pneumonitis,\(^107,108\)) or diagnosed without) must include a careful clinical history, the rise of antibody titers against the infectious agent, or occasionally on the direct identification of the infectious agent on pathology. All drugs taken in the last 3 months preceding the symptoms must be systematically recorded.\(^119\) Radiation therapy to the breast after tumorectomy for cancer may precipitate the development of OP in \(\sim\)2.5% of treated women and a mean delay of 3 to 6 months after the completion of irradiation.\(^120\) Radiation-induced OP clearly differs from radiation pneumonitis because it may involve nonirradiated areas of the lung, may be migratory, and rapidly clears with CS therapy (while radiation pneumonitis is limited to the radiation field and results in retractile consolidation with traction bronchiectasis). Among the group of connective tissue diseases, OP occurs mainly in cases where intraalveolar organization is the predominant pattern, and assessing the significance of OP may be difficult in small biopsy specimen.

**Management in the Absence of a Lung Biopsy**

A reasonable alternative to lung biopsy is represented by patient management in the absence of confirmation of the histopathology of OP, an approach commonly used in the community. Because of the risk of misdiagnosing alternative conditions that may mimic OP, only typical cases at imaging (e.g., multiple patchy consolidation) with compatible clinical and BAL features should be treated without biopsy. Patients must be informed that the diagnosis is only probable, and that careful follow-up is necessary. Furthermore, particular attention must be paid to any clue of alternate diagnosis, including peripheral blood or BAL eosinophilia, microbiology of BAL, and especially unusual evolution (e.g., incomplete response to CSs or relapse despite \(\sim 20\) mg/d of oral prednisone). In patients receiving CS therapy for probable COP in the absence of histopathological confirmation, rapid improvement is often considered to reinforce the diagnosis of OP, although it is not specific (as similar improvement can occur with CSS in CEP).

**Exclusion of Possible Causes**

The approach to patients with OP (be it established by biopsy or diagnosed without) must include a careful clinical history and inquiry for infections (Table 3), drugs (Table 4), and the presence of comorbid diseases (Table 5) such as CTD (including *formes frustes* of, or undifferentiated CTD), cancer, thoracic radiotherapy for breast cancer, exposure to drugs, inflammatory bowel disease, aspiration, or less common conditions such as common variable immune deficiency or toxic exposures (e.g., titanium nanoparticles, acetic acid).\(^111,116\) Because the clinical, laboratory, and imaging features and outcome of secondary OP generally parallel those of COP,\(^117,118\) a careful etiologic inquiry is necessary in any OP without evident cause and especially in case of relapsing OP.

A histopathology of OP especially prompts a search for infectious agents; however, the infection is no longer active at the time of OP, and the diagnosis of the infection may be based on the clinical history, the rise of antibody titers against the infectious agent, or occasionally on the direct identification of the infectious agent on pathology. All drugs taken in the weeks or months preceding the symptoms must be systematically recorded.\(^119\) Radiation therapy to the breast after tumorectomy for cancer may precipitate the development of OP in \(\sim\)2.5% of treated women and a mean delay of 3 to 6 months after the completion of irradiation.\(^120\) Radiation-induced OP clearly differs from radiation pneumonitis because it may involve nonirradiated areas of the lung, may be migratory, and rapidly clears with CS therapy (while radiation pneumonitis is limited to the radiation field and results in retractile consolidation with traction bronchiectasis). Among the group of connective tissue diseases, OP occurs mainly in cases where intraalveolar organization is the predominant pattern, and assessing the significance of OP may be difficult in small biopsy specimen.
One common and recently emphasized cause of OP is aspiration pneumonia. OP is a frequent pathological feature in patients with occult aspiration pneumonia related to food or other particulate matter. Aspiration pneumonia seems to be a more frequent cause of OP than previously suspected. Because it is evident clinically in only <10% of cases, predisposing factors for aspiration should be sought (e.g., esophageal or gastric causes, drug use, neurological conditions). The presence of multinucleated giant cells, acute bronchopneumonia or bronchiolitis, or suppurative granulomas in a background of OP should prompt the pathologist to look for foreign material and particulate matters on the lung biopsy, and the clinician to evaluate for possible aspiration.

Table 3 Main Infectious Agents That Cause Organizing Pneumonia

<table>
<thead>
<tr>
<th>Bacteria</th>
<th>Streptococcus pneumoniae</th>
<th>Actinomyces israelii</th>
<th>Chlamydia pneumoniae</th>
<th>Coxiella burnetii</th>
<th>Legionella pneumophila</th>
<th>Mycoplasma pneumonia</th>
<th>Nocardia asteroides</th>
<th>Staphylococcus aureus</th>
<th>Serratia marcescens</th>
<th>Pseudomonas aeruginosa</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viruses</td>
<td>Human immunodeficiency virus</td>
<td>Influenza virus</td>
<td>Parainfluenza virus</td>
<td>Herpesvirus</td>
<td>Hepatitis C virus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parasites</td>
<td>Plasmodium vivax</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fungi</td>
<td>Cryptococcus neoformans</td>
<td>Penicillium janthinellum</td>
<td>Pneumocystis jiroveci (in AIDS)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 4 Main Drugs That Cause Organizing Pneumonia

<table>
<thead>
<tr>
<th>Drug</th>
<th>identified causes</th>
<th>Clinical settings</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-aminosalicylic acid</td>
<td>Infections (see Table 3)</td>
<td>Occult aspiration pneumonia</td>
</tr>
<tr>
<td>Amiodarone</td>
<td>Drugs (see Table 4)</td>
<td>Connective tissue disease</td>
</tr>
<tr>
<td>Amphotericin B</td>
<td>Distal to airways obstruction</td>
<td>Primary biliary cirrhosis</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>Fumes and toxic exposures (e.g., aerosolized textile dye Acramin FWN; mustard gas)</td>
<td>Inflammatory bowel diseases (ulcerative colitis; Crohn disease)</td>
</tr>
<tr>
<td>Bleomycin</td>
<td>Transplantation (lung, liver), bone marrow graft</td>
<td>Hematologic malignancies (leukemias, myeloblastic, lymphoblastic myelomonocytic, T cell; Hodgkin disease)</td>
</tr>
<tr>
<td>Busulfan</td>
<td>Cancers and postthoracic radiotherapy, especially for breast cancer</td>
<td>Hypersensitivity pneumonitis</td>
</tr>
<tr>
<td>Carbamazepine</td>
<td>Eosinophilic pneumonia</td>
<td>Others: common variable immune deficiency, Sweet syndrome, polymyalgia rheumatica, Behçet disease, thyroid diseases, vasculitis, sarcoidosis</td>
</tr>
<tr>
<td>Dihydroergocryptin</td>
<td>Chronic bronchiolitis</td>
<td></td>
</tr>
<tr>
<td>Everolimus</td>
<td>Others: other causes</td>
<td></td>
</tr>
<tr>
<td>Interferon-α</td>
<td>Other causes</td>
<td></td>
</tr>
<tr>
<td>Interferon-β</td>
<td>Other causes</td>
<td></td>
</tr>
<tr>
<td>Mesalazine</td>
<td>Other causes</td>
<td></td>
</tr>
<tr>
<td>Methotrexate</td>
<td>Other causes</td>
<td></td>
</tr>
</tbody>
</table>

For a complete list, visit www.pneumotox.com.

Table 5 Miscellaneous Causes and Clinical Settings Associated with Organizing Pneumonia

<table>
<thead>
<tr>
<th>Identified causes</th>
<th>Clinical settings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections (see Table 3)</td>
<td>Occult aspiration pneumonia</td>
</tr>
<tr>
<td>Drugs (see Table 4)</td>
<td>Connective tissue disease</td>
</tr>
<tr>
<td>Distal to airways obstruction</td>
<td>Primary biliary cirrhosis</td>
</tr>
<tr>
<td>Fumes and toxic exposures (e.g., aerosolized textile dye Acramin FWN; mustard gas)</td>
<td>Inflammatory bowel diseases (ulcerative colitis; Crohn disease)</td>
</tr>
<tr>
<td>Transplantation (lung, liver), bone marrow graft</td>
<td>Hematologic malignancies (leukemias, myeloblastic, lymphoblastic myelomonocytic, T cell; Hodgkin disease)</td>
</tr>
<tr>
<td>Cancers and postthoracic radiotherapy, especially for breast cancer</td>
<td>Hypersensitivity pneumonitis</td>
</tr>
<tr>
<td>Eosinophilic pneumonia</td>
<td>Others: common variable immune deficiency, Sweet syndrome, polymyalgia rheumatica, Behçet disease, thyroid diseases, vasculitis, sarcoidosis</td>
</tr>
</tbody>
</table>

Table 6 Miscellaneous Causes and Clinical Settings Associated with Organizing Pneumonia

<table>
<thead>
<tr>
<th>Identified causes</th>
<th>Clinical settings</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infections (see Table 3)</td>
<td>Occult aspiration pneumonia</td>
</tr>
<tr>
<td>Drugs (see Table 4)</td>
<td>Connective tissue disease</td>
</tr>
<tr>
<td>Distal to airways obstruction</td>
<td>Primary biliary cirrhosis</td>
</tr>
<tr>
<td>Fumes and toxic exposures (e.g., aerosolized textile dye Acramin FWN; mustard gas)</td>
<td>Inflammatory bowel diseases (ulcerative colitis; Crohn disease)</td>
</tr>
<tr>
<td>Transplantation (lung, liver), bone marrow graft</td>
<td>Hematologic malignancies (leukemias, myeloblastic, lymphoblastic myelomonocytic, T cell; Hodgkin disease)</td>
</tr>
<tr>
<td>Cancers and postthoracic radiotherapy, especially for breast cancer</td>
<td>Hypersensitivity pneumonitis</td>
</tr>
<tr>
<td>Eosinophilic pneumonia</td>
<td>Others: common variable immune deficiency, Sweet syndrome, polymyalgia rheumatica, Behçet disease, thyroid diseases, vasculitis, sarcoidosis</td>
</tr>
</tbody>
</table>

**Treatment**

**Corticosteroid Treatment**

CS treatment represents the standard therapy in COP. Initiation of therapy results in dramatic clinical improvement in typical COP, with regression of symptoms within days. Imaging improves rapidly, with consolidation evolving to ground glass and eventually regressing completely within a month without significant sequelae. The overall prognosis of typical COP is excellent (whereas the outcome is less favorable in patients with secondary OP). Patients with airspace opacities at imaging have a particularly good outcome. The less frequent linear or reticular opacities may not resolve. Presence of interstitial fibrosis at pathology or of septal thickening and remodeling at CT is associated with persistent disease.

The doses and duration of CS treatment have not been established, and treatment should aim at the optimal balance between disease control and side effects. In the past, the initial doses of prednisone have varied from 0.75 to 1.5 mg/kg/d. Because response to CS is dramatic in most cases, the current approach is to avoid intense and prolonged CS treatment, to limit the risk of iatrogenic complications. We therefore start with prednisone, 0.75 mg/kg/d for 4 weeks, then progressively decrease for a total duration of treatment of 24 weeks (Table 6). We now tend to use a shorter treatment protocol, starting with 0.75 mg/kg/d of prednisone and tapered over a total of 12 weeks, possibly associated with clarithromycin. Other treatment protocols with slower decrease of therapy have been proposed. High-dose intravenous methylprednisolone is often used as initial therapy in patients with rapidly progressive COP. Spontaneous improvement over 3 to 6 months has been reported in COP.
however, clinical monitoring without therapy is not recommended except in patients with no symptoms or mild radiographic findings.129

Focal COP does not require CS therapy after surgical resection of the lesion (performed for suspicion of lung cancer).4,41,130 Secondary OP requires treatment of the underlying condition (CTD, infection) or withdrawal of the causative drug or exposure,41 and may require a shorter treatment if the offending agent has been withdrawn.131

Immunosuppressive Therapy
Although most cases of typical COP with alveolar consolidation have a rapid favorable outcome with CS therapy, a minority of patients have persistent disease, especially those with reticulation on HRCT or with the fibrosing/progressive variant of COP. In this situation, cyclophosphamide or azithromycin may be used as an adjunct to CS therapy, which is usually continued at a low dose (~0.25 mg/kg/d of oral prednisone).132 However, the possible benefit of immunosuppressive therapy has not been evaluated.

Management of Relapses
Relapse occurs in 13 to 58% of patients with COP on decreasing or after stopping CS,40,41 and ~20% of patients experience more than one episode of relapse.40 Delayed treatment, mild cholestasis,40 and severe hypoxemia133 have been reported to be associated with a higher risk of relapse. Relapses are not associated with increased morbidity or mortality. Dramatic response to resumed therapy is observed in most cases, and doses of 20 mg per day of prednisone (with progressive decrease) suffice to treat the relapse in most cases. Importantly, any relapse should prompt a search for a persisting cause of OP, especially drug intake. Relapses occurring while receiving more than 15 to 30 mg of prednisone per day (depending on body weight) should prompt extensive reappraisal of the diagnosis (especially the search for a cause) and clinical-radiological-pathological discussion, especially when a large sample is not available for histopathology.

Table 6  Proposed Therapeutic Regimen for Typical Cryptogenic Organizing Pneumonia

<table>
<thead>
<tr>
<th>Step</th>
<th>Duration (weeks)</th>
<th>Doses of Prednisone</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>4</td>
<td>0.75 mg/kg/d</td>
</tr>
<tr>
<td>2</td>
<td>4</td>
<td>0.5 mg/kg/d</td>
</tr>
<tr>
<td>3</td>
<td>4</td>
<td>20 mg/d</td>
</tr>
<tr>
<td>4</td>
<td>6</td>
<td>10 mg/d</td>
</tr>
<tr>
<td>5</td>
<td>6</td>
<td>5 mg/d</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment of relapse</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>12</td>
<td>20 mg/d</td>
</tr>
<tr>
<td>2</td>
<td>6</td>
<td>10 mg/d</td>
</tr>
<tr>
<td>3</td>
<td>6</td>
<td>5 mg/d</td>
</tr>
</tbody>
</table>

Macrolides
Macrolides have been suggested for their anti-inflammatory properties as an alternative option in patients who are intolerant of CSs or who frequently relapse.134 However, the effect of macrolide therapy has been reported in fewer than 50 patients, including a majority with COP and some with secondary OP especially radiation-induced OP.134–139 Therapy consisted of erythromycin at a dose of 600 mg daily for 3 to 4 months,136 clarithromycin 500 mg twice daily, or azithromycin.129,134 Tolerance and safety of macrolides were generally good. The response rate of patients receiving macrolide therapy and the potential influence of macrolides on long-term outcome of COP cannot be assessed, and conclusions are limited by the observational design and heterogeneity of studies and by reporting bias. Thus the available evidence does not support the use of macrolide therapy in patients with COP. In addition, the benefit initially observed in case reports is not confirmed by the empirical routine use of these drugs.

Variants of Organizing Pneumonia

Fibrosing Variant of Organizing Pneumonia (Severe Organizing Pneumonia)
Cases of COP have been reported that do not completely resolve and have the potential to cause severe or fulminant respiratory failure requiring mechanical ventilation, occasionally leading to death.140 Such cases only exceptionally correspond to genuine OP pathological lesions, and are characterized by residual or progressive interstitial fibrosis associated with OP lesions.4,41,127,140 These cases may correspond to an overlap between OP and interstitial fibrosis as described in seven of 16 patients who had a clinical and histological diagnosis of COP.4 In patients with acute exacerbation of IPF, features of DAD or OP are found in association with preexisting UIP.141 Such cases may also represent overlap of COP with acute respiratory distress syndrome with pathological features of DAD undergoing organization,141 fibrotic NSIP,142 or acute fibrous OP.104

In such cases, the response to CS is not as favorable as in classical COP. Immunosuppressive agents (especially cyclophosphamide) are usually added to CSs (often used at a higher dose, starting with 1 to 2 mg/kg/d of intravenous methylprednisolone) with variable outcome.

Acute Fibrinous Organizing Pneumonia
Acute fibrinous OP is a histopathological pattern first reported in patients with acute respiratory failure, with predominantly basal and bilateral areas of consolidation at imaging. It is characterized histologically by abundant fibrin deposition within the alveolar airspaces, with hyperplasia of type II pneumocytes, associated OP, and absence of hyaline membranes (which are the hallmark of DAD).104 One case of acute fibrinous OP presenting as a localized mass has been reported.143 Acute fibrinous OP is currently considered a pathological variant of OP that may be associated with a more rapidly progressing disease. Similarly to OP, it may be...
encountered in the context of various underlying conditions, including infection, eosinophilic pneumonia, or vasculitis, or in the surrounding of pulmonary infarction.

Of note, other conditions usually considered as variants of OP have been reported, including bronchiolitis with interstitial pneumonitis\(^{14,15}\) and bronchiolitis–peribronchiolar OP.\(^{146}\)

References

64 Norman D, Plecyk M, Roberts DH. Eosinophilic pneumonia as an initial manifestation of rheumatoid arthritis. Chest 2004; 126(3):993–995
68 Price J. Round pneumonia and focal organizing pneumonia are different entities. AJR Am J Roentgenol 1999;172(2):549–550
Cryptogenic Organizing Pneumonia

Cottin, Cordier


79 Cottin V. Idiopathic eosinophilic pneumonias. Eur Respir Mon 2011;54:118–139


99 Dostader EE, Mukhopadhyay S, Katzenstein AL. Core needle biopsy in benign lung lesions: pathologic findings in 159 cases. Hum Pathol 2010;41(11):1530–1535


115 Sheu BF, Lee CC, Young YR, Li LF, Chang SS. Delayed-onset bronchiolitis obliterans with organizing pneumonia associated...


